Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Clinical Immunology · Immunodeficiency 99

Treating IMD99: Balancing Infection and Autoimmunity

At a Glance

IMD99 treatment balances low antibody protection against infections with control of autoimmune attacks on red blood cells and platelets. Care may combine IVIG or SCIG with carefully monitored steroids, rituximab, or selected targeted medicines, tailored to each person’s risks.

Treating Immunodeficiency 99 (IMD99) is a delicate balancing act. Your medical team must solve two opposite problems at once: they must “boost” your defense against germs while “quieting” the parts of your immune system that are attacking your own blood cells [1][2].

Because there is no universal protocol for such a rare condition, your treatment is built in layers, tailored to your molecular diagnosis, age, and phenotype.

Layer 1: Restoring Your Defense

If indicated by clinical and functional tests, a priority is typically Immunoglobulin Replacement Therapy (IgRT). This treatment provides the antibodies (IgG) your body cannot make on its own [3].

  • How it Works: You receive antibodies collected from healthy donors. This can be done through a vein (IVIG) every 3–4 weeks or under the skin (SCIG) once or twice a week [4].
  • The Goal: The aim is to reach an individualized “trough” level (your baseline antibody count just before your next dose) that is high enough to reduce severe infections [5]. Goals are based on infection control as well as laboratory values.
  • A Critical Note: While replacement-dose IgRT is excellent at preventing infections, it generally does not stop your immune system from attacking your blood cells [6] (though high-dose IVIG can sometimes be used as an immunomodulatory treatment for selected immune cytopenias).
  • Risks: Treatment carries risks of infusion or injection reactions, and rare renal, thrombotic, hemolytic, or aseptic-meningitis complications.

Layer 2: Managing the Overactive System

When your immune system attacks your red blood cells or platelets (autoimmune cytopenia), doctors must use medications that suppress or “re-program” that response. Do not stop or taper medicines on your own.

Corticosteroids

Steroids (like prednisone) are often used to stop an active attack on your blood cells [1]. They work quickly but carry a dose-dependent risk of infection. Doctors try to use the lowest effective dose for the shortest time possible to avoid long-term side effects [7]. You will need monitoring for glucose, blood pressure, and infection risk.

B-Cell Depletion Therapy

If steroids aren’t enough, doctors may consider Rituximab. This drug broadly depletes CD20-positive B cells [8].

  • The Risk: Rituximab can cause prolonged B-cell depletion and cause your already low antibody levels to drop further, and may prevent you from responding to vaccines [9][5]. It also carries a risk of Hepatitis B reactivation.
  • The Monitoring: While on this therapy, your team will closely monitor your B-cell counts and may increase your IgRT dose to compensate for the extra suppression [5].

Pathway-Directed Therapies

In some cases of selected immune-dysregulation disorders, doctors may use “precision” drugs. Drugs like sirolimus or abatacept are sometimes used as specialist-considered options tied to particular molecular diagnoses [10][11]. They require close renal, blood-count, metabolic, and drug-interaction monitoring.

The Decision-Tree Framework

Your doctors generally follow a “stepped” approach to balance these risks. Every time a new immunosuppressant is added, the “protection” side of the scale must be adjusted.

  1. Assess Infection Risk: Before starting suppression, doctors screen for hidden infections (like Hepatitis B or TB) that could flare up when the immune system is quieted [12].
  2. Add Protection: When indicated by the medication and risk profile, your doctor may prescribe prophylactic antibiotics (like Bactrim/Septra) to prevent specific types of pneumonia [12]. Be aware that trimethoprim-sulfamethoxazole can itself cause rash, liver injury, neutropenia, or thrombocytopenia.
  3. Monitor the Balance: You will likely have frequent blood draws to ensure your blood counts are rising while your antibody levels stay high enough to keep you safe [5].
Treatment Goal Typical Medications Major Considerations
Prevent Infection IVIG, SCIG, Antibiotics Replacement dose does not treat the autoimmune attack.
Stop Active Attack Corticosteroids Increases infection risk; requires careful tapering and glucose monitoring.
Long-term Control Rituximab, Sirolimus Can cause prolonged low antibody levels; requires strict monitoring.

The most important part of this journey is open communication. If you feel a new infection starting or see new bruises while your treatment is being adjusted, notify your immunology team immediately. Balancing these two sides of the immune system is a dynamic process that requires constant fine-tuning [13].

Common questions in this guide

How is IMD99 treated when I have both infections and autoimmune cytopenias?
Treatment often has two goals: immunoglobulin replacement may reduce serious infections when antibody levels are low, while medicines such as corticosteroids or rituximab control the immune attack on blood cells. Some people may be considered for sirolimus or abatacept based on their molecular diagnosis. The plan is individualized and adjusted using infection history, blood counts, and antibody levels.
Can immunoglobulin replacement stop my autoimmune cytopenias?
Replacement-dose immunoglobulin, given as IVIG or SCIG, is mainly used to reduce infection risk when the body cannot make enough antibodies, and it usually does not stop the autoimmune attack on red cells or platelets. High-dose IVIG may sometimes be used as a separate immune-modulating treatment for selected cytopenias. Your team decides which dose and purpose applies to you.
What should I know about rituximab if my antibody levels are already low?
Rituximab removes CD20-positive B cells and can make low antibody levels fall further. It may also reduce vaccine responses and allow hepatitis B to reactivate, so clinicians may screen for infection and monitor B-cell and antibody levels. If needed, they may adjust immunoglobulin replacement while you receive it.
Will I need preventive antibiotics while taking immune-suppressing medicine?
Some people are prescribed preventive antibiotics, such as trimethoprim-sulfamethoxazole, when their medicines and infection risk make prevention appropriate. Before immunosuppression, clinicians may screen for hidden infections such as hepatitis B or tuberculosis. Trimethoprim-sulfamethoxazole can cause rash, liver injury, or low blood cell counts, so follow your monitoring instructions and report concerning symptoms.
What is an IgG trough level, and why does it matter in IMD99?
An IgG trough is the antibody level measured just before your next immunoglobulin dose. Your target is individualized using infection control and laboratory results, rather than a single number that fits everyone. The goal is enough protection to reduce serious infections while your other treatments are adjusted.
How should steroids be tapered for autoimmune cytopenias?
Steroids such as prednisone can act quickly, but the dose should be reduced only according to your clinician’s plan. Do not stop or taper them on your own. Clinicians aim for the lowest effective dose for the shortest time and may monitor glucose, blood pressure, blood counts, and infection risk.

Get notified when new evidence is published on immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    [Treatment of ITP and AIHA in CVID: A systematic literature review].

    Lacombe V, Lozac'h P, Orvain C, et al.

    La Revue de medecine interne 2019; (40(8)):491-500 doi:10.1016/j.revmed.2019.02.006.

    PMID: 31101329
  2. 2

    Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study.

    Tsilifis C, Speckmann C, Lum SH, et al.

    The Journal of allergy and clinical immunology 2024; (154(6)):1534-1544 doi:10.1016/j.jaci.2024.08.020.

    PMID: 39218359
  3. 3

    Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.

    Pecoraro A, Crescenzi L, Granata F, et al.

    International immunopharmacology 2017; (52()):136-142 doi:10.1016/j.intimp.2017.09.005.

    PMID: 28898770
  4. 4

    Immunoglobulin therapy for immunodeficiency.

    Wilson BE, Freeman CM

    Allergy and asthma proceedings 2024; (45(5)):364-370 doi:10.2500/aap.2024.45.240053.

    PMID: 39294913
  5. 5

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  6. 6

    Autoimmunity in common variable immunodeficiency.

    Agarwal S, Cunningham-Rundles C

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2019; (123(5)):454-460 doi:10.1016/j.anai.2019.07.014.

    PMID: 31349011
  7. 7

    [Enteroviral infections in adults treated with rituximab: A new case of chronic meningitis and myofasciitis and literature review].

    Maillet F, Pineton De Chambrun M, Monzani Q, et al.

    La Revue de medecine interne 2020; (41(3)):200-205 doi:10.1016/j.revmed.2019.12.018.

    PMID: 31980187
  8. 8

    Immunosuppressive therapy with rituximab in common variable immunodeficiency.

    Pecoraro A, Crescenzi L, Galdiero MR, et al.

    Clinical and molecular allergy : CMA 2019; (17()):9 doi:10.1186/s12948-019-0113-3.

    PMID: 31080365
  9. 9

    Infectious complications of rituximab therapy in renal disease.

    Nixon A, Ogden L, Woywodt A, Dhaygude A

    Clinical kidney journal 2017; (10(4)):455-460 doi:10.1093/ckj/sfx038.

    PMID: 28852481
  10. 10

    Therapeutic options for CTLA-4 insufficiency.

    Egg D, Rump IC, Mitsuiki N, et al.

    The Journal of allergy and clinical immunology 2022; (149(2)):736-746 doi:10.1016/j.jaci.2021.04.039.

    PMID: 34111452
  11. 11

    Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.

    Bride KL, Vincent T, Smith-Whitley K, et al.

    Blood 2016; (127(1)):17-28 doi:10.1182/blood-2015-07-657981.

    PMID: 26504182
  12. 12

    Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders.

    Malpica L, van Duin D, Moll S

    American journal of hematology 2019; (94(12)):1396-1412 doi:10.1002/ajh.25642.

    PMID: 31571266
  13. 13

    [Chinese expert consensus on the diagnosis and treatment of severe pneumonia in immunocompromised hosts].

    ,

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2026; (49(2)):113-130 doi:10.3760/cma.j.cn112147-20250729-00449.

    PMID: 41629088

This page provides general information about treating IMD99 and does not constitute medical advice. Your immunologist and hematologist should tailor immunoglobulin, immunosuppressive, and infection-prevention treatment to your specific results.